Oyster Point raises $93 million in Series B financing

Oyster Point Pharma has completed $93 million in Series B financing, the company announced in a press release.
Co-led by Invus Opportunities and Flying L Partners in collaboration with Falcon Vision, as well as existing investors New Enterprise Associates and Versant Ventures and new investor Vida Ventures, the funding will be used to support the company’s dry eye disease product portfolio.
Oyster Point’s lead product candidates, OC-01 and OC-02, both delivered via nasal spray, are designed to stimulate the trigeminal parasympathetic pathway to promote natural tear film production,

Full Story →